TrialLancet (London, England)2025

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

David J Lewis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.